首页> 外文期刊>Prescrire international >Drugs for hepatitis C: it's time to slash prices!
【24h】

Drugs for hepatitis C: it's time to slash prices!

机译:丙型肝炎的药物:是时候削减价格了!

获取原文
获取原文并翻译 | 示例
           

摘要

When so-called direct-acting antiviral drugs against hepatitis C came onto the market around 2015, some stakeholders hailed them as a means of eradicating this disease (1). Where do we stand a few years later? Prices designed for shareholders. Sofosbuvir (Sovaldi0) was marketed in the United States at the exorbitant price of 1000 dollars per day, reflecting the stock market speculation to which this drug gave rise (2). In 2015, stock markets applauded the performance of Gilead whose share price increased by 157% in two years thanks to Sovaldi0 and Harvoni0 (sofosbuvir and ledipasvir) (3). This company's real strategy was to seek maximum profits in the richest countries and not disease eradication, which would require very low prices to allow access to treatment by the largest number of people.
机译:当被称为丙型肝炎的所谓的直接抗病毒药物到2015年来市场时,一些利益相关者被称为消除这种疾病的手段(1)。 几年后我们在哪里? 为股东设计的价格。 Sofosbuvir(Sovaldi0)以每天1000美元的高昂价格在美国销售,反映了该药物产生的股票市场炒作(2)。 2015年,由于Soverdi0和Harvoni0(Sofosbuvir和LedipaSvir)(Sofosbuvir和Ledipasvir)(3),股票市场赞扬了Gilead的表现,其股价在两年内增加了157%。 该公司的真正战略是在最富有国家寻求最大的利润,而不是疾病根除,这需要非常低的价格来允许获得最多人数的治疗。

著录项

  • 来源
    《Prescrire international》 |2018年第199期|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号